Citations

Showing 10 of 108119 citations.

The Emerging Role of Nurse Practitioners and Physician Assistants in Liver Transplantation
Chaney, Amanda , Yataco, Maria, Chaney, Amanda J , Yataco, Maria L

Mayo Clinic

Liver Transplantation | April 23, 2019 | Volume: 25 | Issue: 7 | Pages: 1105-1109

10.1002/lt.25474 | PMID 31013382 Get It

The evolving role of nurse practitioners (NPs) and physician assistants (PAs) in the United States continues to progress. NP and PA responsibilities have expanded from primary care practices to medical and surgical specialties. They provide acute care in hospitals and intensive care units, and they serve as educators, lobbyists, and researchers. Questions have arisen from NP/PA leaders, physician leaders, and administrators on how to best implement a successful NP/PA model within their practice. This article reviews some common themes in the literature by looking at the current state of NP/PA practice, outlines some practice models established therein, and provides recommendations for implementing a successful NP/PA model in a liver transplant practice.
The Gut‐Liver Axis in Primary Sclerosing Cholangitis: Are Pathobionts the Missing Link?
O’Hara, Steven P. , LaRusso, Nicholas F.

Mayo Clinic

Hepatology | April 23, 2019 | Volume: 70 | Issue: 3 | Pages: 1058-1060

10.1002/hep.30673 | PMID 31013359 Get It

Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma
Davis, Lara E. , Ryan, Christopher W. , Ganjoo, Kristen N. , Chawla, Sant P. , Agulnik, Mark , Livingston, Michael B. , Keedy, Vicky L., Rushing, Daniel A., Okuno, Scott H. , Riedel, Richard F. , Attia, Steven , Mascarenhas, Leo , Maki, Robert G. , Maki, Robert G , Riedel, Richard F , Davis, Lara E , Mascarenhas, Leo , Bolejack, Vanessa , Loggers, Elizabeth T , Reed, Damon R. , Reinke, Denise K.

Mayo Clinic

Journal of Clinical Oncology | April 23, 2019 | Volume: 37 | Issue: 16 | Pages: 1424-1431

10.1200/jco.18.02374 | PMID 31013172 Get It

PURPOSE SARC024 is a phase II clinical trial of the multikinase inhibitor regorafenib in specific sarcoma subtypes, including advanced osteosarcoma. We hypothesized that regorafenib would improve progression-free survival (PFS) in patients with sarcoma and report the results of the osteosarcoma cohort. PATIENTS AND METHODS This trial enrolled patients with progressive metastatic osteosarcoma with measurable disease by RECIST who had received at least one prior line of therapy. Patients were randomly assigned at a ratio of one to one to regorafenib or placebo. Crossover was allowed at time of disease progression. PFS was the primary end point of the study, which was powered to detect a difference of at least 3 months in median PFS. RESULTS Forty-two patients from 12 centers were enrolled between September 2014 and May 2018. Median age was 37 years (range, 18 to 76 years). Patients had received an average of 2.3 prior therapy regimens. Ten patients receiving placebo crossed over to active drug at time of progression. Study enrollment was stopped early, after a data safety monitoring committee review. Median PFS was significantly improved with regorafenib versus placebo: 3.6 months (95% CI, 2.0 to 7.6 months) versus 1.7 months (95% CI, 1.2 to 1.8 months), respectively (hazard ratio, 0.42; 95% CI, 0.21 to 0.85; P = .017). In the context of the crossover design, there was no statistically significant difference in overall survival. Fourteen (64%) of 22 patients initially randomly assigned to regorafenib experienced grade 3 to 4 events attributed to treatment, including one grade 4 colonic perforation. CONCLUSION The study met its primary end point, demonstrating activity of regorafenib in patients with progressive metastatic osteosarcoma. No new safety signals were observed. Regorafenib should be considered a treatment option for patients with relapsed metastatic osteosarcoma.
Aspirin dosage for the prevention of graft occlusion in people undergoing coronary surgery
Jazayerli, Mhd Luay, Mallak, Mahmoud, Haydour, Qusay, Alahdab, Fares , Alhalabi, Omar , Hasan, Somar M. , Alkhouli, Mohamad , Murad, M. Hassan

Mayo Clinic

Cochrane Database of Systematic Reviews | April 23, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/14651858.cd012113.pub2 Get It

US State Regulation of Decisions for Pregnant Women Without Decisional Capacity
DeMartino, Erin S. , Sperry, Beau P. , Doyle, Cavan K. , Chor, Julie , Kramer, Daniel B. , Mueller, Paul S. , Dudzinski, David M.

Mayo Clinic

JAMA | April 23, 2019 | Volume: 321 | Issue: 16 | Pages: 1629

10.1001/jama.2019.2587 | PMID 31012920 Get It

Subcutaneous adipose tissue free fatty acid uptake measured using positron emission tomography and adipose biopsies in humans
Cao, Yanli , Gathaiya, Nicola, Han, Qiaojun, Kemp, Bradley J. , Jensen, Michael D.

Mayo Clinic

American Journal of Physiology-Endocrinology and Metabolism | April 23, 2019 | Volume: 317 | Issue: 2 | Pages: E194-E199

10.1152/ajpendo.00030.2019 | PMID 31013145 Get It

Positron emission tomography (PET) radiopharmaceuticals can noninvasively measure free fatty acid (FFA) uptake into adipose tissue. We studied 29 volunteers to test whether abdominal and femoral subcutaneous adipose tissue FFA uptake measured using [1- 11 C]palmitate PET agrees with FFA storage rates measured using an intravenous bolus of [1- 14 C]palmitate and adipose biopsies. The dynamic left ventricular cavity PET images combined with blood sample radioactivity corrected for the 11 CO 2 content were used to create the blood time activity curve (TAC), and the constant ( K i ) was determined using Patlak analysis of the TACs generated for regions of interest in abdominal subcutaneous fat. These data were used to calculate palmitate uptake rates in abdominal subcutaneous adipose tissue (µmol·kg −1 ·min −1 ). Immediately after the dynamic imaging, a static image of the thigh was taken to measure the standardized uptake value (SUV) in thigh adipose tissue, which was scaled to each participant’s abdominal adipose tissue SUV to calculate thigh adipose palmitate uptake rates. Abdominal adipose palmitate uptake using PET [1- 11 C]palmitate was correlated with, but significantly ( P < 0.001) greater than, FFA storage measured using [1- 14 C]palmitate and adipose biopsy. Thigh adipose palmitate measured using PET calculation was positively correlated ( R 2 = 0.44, P < 0.0001) with and not different from the biopsy approach. The relative differences between PET measured abdominal subcutaneous adipose tissue palmitate uptake and biopsy-measured palmitate storage were positively correlated ( P = 0.03) with abdominal subcutaneous fat. We conclude that abdominal adipose tissue FFA uptake measured using PET does not equate to adipose FFA storage measured using biopsy techniques.
Computed Tomography Data to Generate a Reproducible, Anatomically Accurate Hemilaryngeal Model
Hintze, Justin M. , Myers, Cheryl , McPhail, Michael, Tchoukalova, Yourka D. , Myers, Cheryl E, McPhail, Michael J., Tchoukalova, Yourka , Hintze, Justin , Lott, David G. , Myers, Cheryl E

Mayo Clinic

Otolaryngology–Head and Neck Surgery | April 23, 2019 | Volume: 161 | Issue: 3 | Pages: 472-477

10.1177/0194599819844974 | PMID 31013207 Get It

ObjectiveThe study aims to demonstrate the reproducibility and feasibility of creating a hemilaryngeal model with a medialized vocal fold (VF) using 3‐dimensional (3D) modeling techniques in both healthy larynges and those affected by cancer.Study DesignThree‐dimensional modeling of human larynges.SettingTertiary academic referral center and regenerative medicine laboratory.Subjects and MethodsComputed tomography (CT) scans from 10 healthy control and 10 patients with laryngeal cancer were segmented and imported into 3D modeling software. The larynx was cut sagittally to create a hemilaryngeal model and the vocal fold medialized. Measurements were taken from the CT and 3D model data and compared.ResultsAll control modeling data closely matched the CT data and were not statistically different from each other. There was a significant correlation between subglottic anteroposterior diameter and VF length (r2 = 0.78, P =. 0008), and it may be a valuable tool to infer true VF dimension in cases where disruption has occurred. The modeling data from patients with cancer did not show statistical difference to the control data, showing that accurate modeling can also be achieved in patients with laryngeal cancer.ConclusionCT scan‐based 3D modeling of the larynx and VF is possible and reproducible. The results closely match those previously reported in the literature and can also be replicated in cases with laryngeal cancer. This study paves the way for future de novo fabricated laryngeal scaffolds that can be synthesized using 3D printers and tailored to meet surgical demands.
Evaluating narrative operative reports for endoscopic sinus surgery in a residency training program
Wheeler, Shannon , Miglani, Amar , Deep, Nicholas L. , Girardo, Marlene , Hinni, Michael L., Wheeler, Shannon C , Hinni, Michael, Lal, Devyani

Mayo Clinic

Laryngoscope Investigative Otolaryngology | April 23, 2019 | Volume: 4 | Issue: 3 | Pages: 279-284

10.1002/lio2.264 | PMID 31236459 Get It

ObjectiveThe narrative operative report (NR) bears testimony to critical elements of patient care. Residents’ NRs also provide insights into their comprehension of the procedure. NR documentation is an informal element of surgical residency training but data regarding quality of such training are scant. We aim to evaluate the NR within a residency training program.MethodsThe quality of NRs for endoscopic sinus surgery (ESS) was evaluated through a retrospective analysis of 90 NRs for ESS. Thirty‐four elements that the attending surgeon regards as “critical” variables, or quality indicators (QIs), that should be documented, were studied to evaluate quality. A “performance metric (PM),” defined as the average percent of QIs dictated/total word count, was determined. Subgroup analysis by the level of training was additionally performed.ResultsSurgical indications, procedural steps, and immediate postoperative findings were accurately documented in 71%, 84%, and 82% of patients, respectively. The attending surgeon had the highest proportion of included key elements (89% ± 6.2%) followed by junior residents (87% ± 5.7%) and then senior residents (80% ± 14%) (P = .008). The attending surgeon also demonstrated the highest PM, followed by senior and then junior residents (P < .0001).ConclusionsThe quality of NRs was found to be high overall, but not “perfect” for either the attending or trainee surgeon. The PM among residents was expectedly lower than the attending surgeon. We propose that a synoptic reporting system that ensures inclusion of key elements may be helpful in training residents (and attendings) in creating comprehensive and efficient NRs.Level of Evidence3
Pharmacogenomics‐Driven Prediction of Antidepressant Treatment Outcomes: A Machine‐Learning Approach With Multi‐trial Replication
Athreya, Arjun P. , Neavin, Drew , Skime, Michelle , Frye, Mark A. , Wang, Liewei , Weinshilboum, Richard M. , Biernacka, Joanna, Bobo, William V. , Neavin, Drew R , Carrillo‐Roa, Tania , Biernacka, Joanna M. , Rush, Augustus John , Binder, Elisabeth B. , Iyer, Ravishankar K. , Weinshilboum, Richard M.

Mayo Clinic

Clinical Pharmacology & Therapeutics | April 23, 2019 | Volume: 106 | Issue: 4 | Pages: 855-865

10.1002/cpt.1482 | PMID 31012492 Get It

We set out to determine whether machine learning–based algorithms that included functionally validated pharmacogenomic biomarkers joined with clinical measures could predict selective serotonin reuptake inhibitor (SSRI) remission/response in patients with major depressive disorder (MDD). We studied 1,030 white outpatients with MDD treated with citalopram/escitalopram in the Mayo Clinic Pharmacogenomics Research Network Antidepressant Medication Pharmacogenomic Study (PGRN‐AMPS; n = 398), Sequenced Treatment Alternatives to Relieve Depression (STAR*D; n = 467), and International SSRI Pharmacogenomics Consortium (ISPC; n = 165) trials. A genomewide association study for PGRN‐AMPS plasma metabolites associated with SSRI response (serotonin) and baseline MDD severity (kynurenine) identified single nucleotide polymorphisms (SNPs) in DEFB1, ERICH3, AHR, and TSPAN5 that we tested as predictors. Supervised machine‐learning methods trained using SNPs and total baseline depression scores predicted remission and response at 8 weeks with area under the receiver operating curve (AUC) > 0.7 (P < 0.04) in PGRN‐AMPS patients, with comparable prediction accuracies > 69% (P ≤ 0.07) in STAR*D and ISPC. These results demonstrate that machine learning can achieve accurate and, importantly, replicable prediction of SSRI therapy response using total baseline depression severity combined with pharmacogenomic biomarkers.
POEMS Syndrome: 2019 Update on diagnosis, risk‐stratification, and management
Dispenzieri, Angela

Mayo Clinic

American Journal of Hematology | April 23, 2019 | Volume: 94 | Issue: 7 | Pages: 812-827

10.1002/ajh.25495 | PMID 31012139 Get It

AbstractDisease OverviewPolyneuropathy, organomegaly, endocrinopathy, M‐protein, skin changes (POEMS) syndrome is a paraneoplastic syndrome due to an underlying plasma cell neoplasm. The major criteria for the syndrome are polyradiculoneuropathy, clonal plasma cell disorder (PCD), sclerotic bone lesions, elevated vascular endothelial growth factor, and the presence of Castleman disease. Minor features include organomegaly, endocrinopathy, characteristic skin changes, papilledema, extravascular volume overload, and thrombocytosis. Diagnoses are often delayed because the syndrome is rare and can be mistaken for other neurologic disorders, most commonly chronic inflammatory demyelinating polyradiculoneuropathy. POEMS syndrome should be distinguished from the Castleman disease variant of POEMS syndrome, which has no clonal PCD and typically little to no peripheral neuropathy but has several of the minor diagnostic criteria for POEMS syndrome.DiagnosisThe diagnosis of POEMS syndrome is made with three of the major criteria, two of which must include polyradiculoneuropathy and clonal PCD, and at least one of the minor criteria.Risk StratificationBecause the pathogenesis of the syndrome is not well understood, risk stratification is limited to clinical phenotype rather than specific molecular markers. Risk factors include low serum albumin, age, pleural effusion, pulmonary hypertension, and reduced eGFR.Risk‐Adapted TherapyFor those patients with a dominant sclerotic plasmacytoma, first line therapy is irradiation. Patients with diffuse sclerotic lesions or disseminated bone marrow involvement and for those who have progression of their disease 3 to 6 months after completing radiation therapy should receive systemic therapy. Corticosteroids are temporizing, but alkylators are the mainstay of treatment, either in the form of low dose conventional therapy or high dose with stem cell transplantation. Lenalidomide shows promise with manageable toxicity. Thalidomide and bortezomib also have activity, but their benefit needs to be weighed against their risk of exacerbating the peripheral neuropathy. Prompt recognition and institution of both supportive care measures and therapy directed against the plasma cell result in the best outcomes.